We initiated tumors in LT;H11LSL-Cas9, PT;H11LSL-Cas9, and T;H11LSL-Cas9 mice to directly assess whether concurrent tumor suppressor alterations modulate the ability of different Kras variants to initiate and drive tumor growth. The gene discussed is KRAS; the disease is neoplasm.